Skip to main content

Find Clinical Trials

Home
Conditions
Communicable Diseases

Clinical trial condition

Communicable Diseases

Explore clinical trials studying Communicable Diseases. Study availability and eligibility vary by location and protocol.

9,149 public trials 552 recruiting studies

Refine in advanced search Browse all conditions

Communicable Diseases trial results

Completed

TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule

NCT00752648

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations: Not specified

View Trial Details

Completed

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

NCT00412646

Conditions: Acquired Immunodeficiency Syndrome, Anti-Retroviral Agents, Blood-Borne Infections, +15 more
Locations: Not specified

View Trial Details

Completed

TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.

NCT00739622

Conditions: AIDS, Acquired Immunodeficiency Syndrome, Blood-Borne Infections, +16 more
Locations: Not specified

View Trial Details

Completed

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

NCT00838760

Conditions: Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
Locations: Not specified

View Trial Details

Completed

TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.

NCT00866853

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations: Not specified

View Trial Details

Completed

TMC125-C223: TMC125 in HIV-1 Infected Subjects

NCT00081978

Conditions: Blood-Borne Infections, Communicable Diseases, Genital Diseases, +12 more
Locations: Not specified

View Trial Details

Completed

TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.

NCT00736905

Conditions: AIDS, Acquired Immunodeficiency Syndrome, Blood-Borne Infections, +16 more
Locations: Not specified

View Trial Details

Completed

Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems

NCT00001097

Conditions: Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations: Univ of Alabama at Birmingham - Pediatric Birmingham, Alabama, United States

Univ of South Alabama Mobile, Alabama, United States

Phoenix Childrens Hosp Phoenix, Arizona, United States

UCSD Med Ctr / Pediatrics / Clinical Sciences La Jolla, California, United States

View all 46 locations

View Trial Details

Completed

Breastfeeding, Antiretroviral, and Nutrition Study

NCT00164736

Conditions: Behavior, Blood-Borne Infections, Breast Feeding, +14 more
Locations: Kamuzu Central Hospital, Bottom Hospital Lilongwe, Malawi

View Trial Details

Completed

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

NCT00703469

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Advanced Clinical Resesarch Institute Anaheim, California, United States

Quest Clinical Research San Francisco, California, United States

Springfield Clinic Infectious Diseases Springfield, Illinois, United States

John Hopkins University School of Medicine, Viral Hepatitis Center Baltimore, Maryland, United States

View Trial Details